Anti-Rheumatic Drugs - Central & Western Europe

Central & Western Europe

The market of Anti-Rheumatic Drugs market in Central & Western Europe is expected to witness significant growth in the coming years.
According to projections, the revenue in this market is estimated to reach US$3.31bn by the year 2024.
Furthermore, it is anticipated that the market will continue to expand at an annual growth rate of 0.77% (CAGR 2024-2029), resulting in a market volume of US$3.44bn by 2029.
When compared to other countries around Worldwide, United States is expected to generate the highest revenue in this market.
It is projected that the revenue United States will amount to approximately US$34,700.00m by the year 2024.
In Central & Western Europe, Germany leads the market for Anti-Rheumatic Drugs with its advanced healthcare system and high demand for innovative treatments.

Key regions: Germany, United States, India, Japan, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Rheumatic Drugs market in Central & Western Europe has been experiencing significant growth in recent years.

Customer preferences: Patients suffering from rheumatoid arthritis and other autoimmune diseases are increasingly seeking treatments that not only alleviate their symptoms but also improve their quality of life. As a result, there is a growing demand for drugs that not only reduce inflammation and pain but also slow down the progression of the disease. Patients are also looking for drugs that have fewer side effects and are more convenient to administer.

Trends in the market: In Germany, the largest market for anti-rheumatic drugs in the region, there has been a shift towards biologic drugs, which are more effective than traditional disease-modifying anti-rheumatic drugs (DMARDs). This trend is expected to continue in the coming years, as more biologic drugs are approved and more patients are prescribed these drugs. In France, on the other hand, there has been a recent increase in the use of biosimilars, which are cheaper versions of biologic drugs. This trend is expected to continue as more biosimilars become available and as the French government continues to incentivize their use.

Local special circumstances: In Italy, there has been a recent push to increase the use of non-steroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for rheumatoid arthritis, in order to reduce the use of more expensive biologic drugs. However, this trend is being driven more by cost considerations than by patient preferences. In the UK, there has been a recent increase in the use of digital health technologies to monitor patients and improve their adherence to treatment. This trend is expected to continue as more patients become comfortable with using these technologies and as more healthcare providers adopt them.

Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Central & Western Europe is being driven by a number of macroeconomic factors. These include an aging population, which is more susceptible to rheumatoid arthritis and other autoimmune diseases, as well as an increase in the prevalence of these diseases due to changes in lifestyle and environmental factors. In addition, there has been an increase in healthcare spending in the region, which has allowed for greater access to expensive biologic drugs. Finally, there has been a growing awareness of the importance of early diagnosis and treatment of rheumatoid arthritis, which has led to more patients seeking treatment and more healthcare providers prescribing anti-rheumatic drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.